Nuvve and VolitionRx release second quarter 2026 financial updates

Nuvve Holding Corp. reported its second quarter 2026 financial results, noting a significant increase in total revenue to $1.23 million, up from $0.33 million in the same period last year. This growth was driven by higher product sales and grants. The company raised $2.5 million through private placement and preferred stock issuance to support operations. Despite revenue growth, gross profit margins decreased to 2.6% from 60.6% in the previous year, and cash operating losses were $7.3 million.

VolitionRx Limited also announced its second quarter 2026 results, highlighting progress in its product pillars. The epigenetics company is currently in discussions with over a dozen diagnostic and liquid biopsy firms regarding potential licensing agreements. VolitionRx noted a collaboration with Sysmex Corporation and is awaiting the peer review of a clinical manuscript regarding its feline lymphoma detection assay, which could trigger a $5 million milestone payment.